Generic Hernexeos Availability
Last updated on Sep 10, 2025.
Hernexeos is a brand name of zongertinib, approved by the FDA in the following formulation(s):
HERNEXEOS (zongertinib - tablet;oral)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: August 8, 2025
Strength(s): 60MG [RLD]
Is there a generic version of Hernexeos available?
No. There is currently no therapeutically equivalent version of Hernexeos available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hernexeos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
Patent 11,608,343
Issued: March 21, 2023
Inventor(s): Wilding; Birgit et al.
Assignee(s): Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) ##STR00001##
wherein the groups R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.Patent expiration dates:
- July 21, 2041✓✓✓
- July 21, 2041
-
N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Patent 12,171,739
Issued: December 24, 2024
Inventor(s): Lyssikatos; Joseph P. et al.
Assignee(s): ARRAY BIOPHARMA INC. (Boulder, CO)This invention provides compounds of Formula I ##STR00001##
wherein B, G, A, E, R.sup.1, R.sup.2, R.sup.3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.Patent expiration dates:
- November 15, 2026✓✓
- November 15, 2026
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 8, 2030 - NEW CHEMICAL ENTITY
More about Hernexeos (zongertinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- FDA approval history
- Drug class: HER2 inhibitors
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
